BioSpace News Archive

Syndax Pharmaceuticals Inc., . (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that data from the PD-(L)1 refractory non-small cell lung cancer (NSCLC) cohort of ENCORE 601 will be presented at the upcoming International Association for the Study of Lung Cancer

Each year, the PruittHealth family of health care providers celebrates a history that spans nearly half a century as they honor caregivers, team members, past leaders and patients through Founder’s Day festivities.

MabSpace Biosciences announced that on August 24th, 2018, MSB2311 was successfully administered to the first Chinese cancer patient at Beijing Cancer Hospital in its China Phase 1 trial.

Shionogi & Co., Ltd. today announced the positive results from Phase II and III studies of baloxavir marboxil for the treatment of influenza in otherwise-healthy patients have been published in the New England Journal of Medicine (NEJM) in the September 6, 2018 issue.

Today, Bon Secours Health System and Mercy Health announce that the two ministries have formed Bon Secours Mercy Health, creating one of the largest health care systems in the country.

Lunaphore Technologies SA, a Swiss medtech firm developing innovative next-generation devices for cancer tissue diagnostics*, announces closing of CHF 5.3M in Series B funding.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Morgan Stanley 16th Annual Global Healthcare Conference at 8:10 a.m. ET on Wednesday, Sept. 12, 2018, in New York City. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will present at the conference.

Pomerantz LLP is investigating claims on behalf of investors of CV Sciences, Inc.

Insulin Dosing Management Solution Adds Real-time Data from iGlucose® for Optimal HbA1c Improvements and Better Patient Outcomes

The global primary sclerosing cholangitis (PSC) treatment market 2018-2022 is expected to post a CAGR of close to 4% during the forecast period, according to the latest market research report by Technavio.